Latest News
ASCO and EHA highlights in myeloma and AL amyloidosis
The American Society of Clinical Oncology Annual Meeting (ASCO2020) is the largest and one of the most important congresses for the oncology community. Many myeloma and AL amyloidosis updates were presented at this congress which was held from 29 to 31 May 2020. Two weeks later, the 25th edition of the European Hematology Association’s annual…
FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patients
Bristol Myers Squibb (BMS) and bluebird bio, Inc have announced that the companies received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory myeloma, which was submitted in March 2020.
Events for 1st June
No Events
Events for 2nd June
No Events
Events for 3rd June
No Events
Events for 4th June
No Events
Events for 5th June
No Events
Events for 6th June
No Events
Events for 7th June
No Events
Events for 8th June
No Events
Events for 9th June
No Events
Events for 10th June
No Events
Events for 11th June
No Events
Events for 12th June
No Events
Events for 13th June
No Events
Events for 14th June
No Events
Events for 15th June
No Events
Events for 16th June
No Events
Events for 17th June
No Events
Events for 18th June
No Events
Events for 19th June
No Events
Events for 20th June
No Events
Events for 21st June
No Events
Events for 22nd June
No Events
Events for 23rd June
No Events
Events for 24th June
No Events
Events for 25th June
No Events
Events for 26th June
No Events
Events for 27th June
No Events
Events for 28th June
No Events
Events for 29th June
No Events
Events for 30th June
No Events